Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients

Davatchi, Fereydoun; Abdollahi, Bahar Sadeghi; Mohyeddin, Mandana; Shahram, Farhad; Nikbin, Behrooz

doi:10.1111/j.1756-185x.2011.01599.x

Cited by 347 publications

(273 citation statements)

References 15 publications

Supporting

Mentioning

251

Contrasting

Unclassified

Order By: Relevance

“…One approach to regenerative *Address correspondence to this author at the Caring Medical and Rehabilitation Services, 715 Lake St., Oak Park IL 60301 USA; Tel: 708-848-7789; Fax: 708-848-7763; E-mail: drhauser@caringmedical.com therapy is to supply affected joints with either autologous chondrocytes or chondrogenic bone marrow-derived mesenchymal stem cells (BMSCs), prepared as a buffy coat fraction of bone marrow with or without ex vivo expansion. Recent preliminary studies support the investigation of these therapies for OA [4][5][6][7][8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

Rationale for Using Direct Bone Marrow Aspirate as a Proliferant for Regenerative Injection Therapy (Prolotherapy)

Hauser

Eteshola²

2013

TOSCJ

View full text Add to dashboard Cite

Adult mesenchymal stem cells (MSCs) obtainable from autologous bone marrow aspirates have generated tremendous interest in the medical and scientific communities in the last two decades and are currently being investigated by a of interested physicians for use in point-of-care stem cell therapies due to their great potential to differentiate into multiple cell lineages such as bone, cartilage, muscle, tendon, and nerve. However, as these stem cells are found in very low numbers in adult tissue, centrifugal concentration or expansion through in vitro culturing has been pursued to obtain higher numbers of efficacious regenerative therapeutic applications. More recently, some physicians and scientists have chosen to explore use for direct injection of un-fractionated, native whole bone marrow aspirate as a strategy in regenerative treatment regimes. This review examines the potential merits and disadvantages of using either concentrated and culture expanded MSCs versus native whole bone marrow aspirate as key proliferant in direct regenerative injection therapy (RIT). Results from a number of published investigations have clearly shown high potential of various deleterious effects on manipulating MSCs obtained from native bone marrow aspirate either by centrifugal forces or expansion through in vitro culturing; moreover, currently used centrifugal concentration techniques do not significantly concentrate MSCs from bone marrow aspirate, thus, defeating the purpose of this manipulative step. On the other hand, preliminary results and observations of using un-fractionated whole bone marrow injection for treatment of various musculoskeletal joint diseases (for example, osteoarthritic joints) suggest that the procedure is safe and potentially efficacious, with no known deleterious effects as yet reported.

show abstract

Section: Introductionmentioning

confidence: 99%

Rationale for Using Direct Bone Marrow Aspirate as a Proliferant for Regenerative Injection Therapy (Prolotherapy)

Hauser

Eteshola²

2013

TOSCJ

View full text Add to dashboard Cite

show abstract

“…28 Anti-CD44, CD45 and CD34 fluorescein isothiocyanate (FITC), anti-CD13 and CD31 phycoerythrin (PE) were all purchased from Dako (Glostrup, Denmark), along with anti-CD105, PE from Serotec (Space Company, Milano, Italy). Flow cytometry was performed on a FacScan (Becton Dickenson, Franklin Lakes, NJ, USA).…”

Section: Immunophenotypingmentioning

confidence: 99%

“…28 In each patient, the most painful knee, or the worse knee on physical examination, was selected as the site of injection. No previous preparation or premedication was given.…”

Section: Injection Of Mscsmentioning

confidence: 99%

“…28 The mononuclear cells of bone marrow were separated by ficoll hypaque density gradient. Vented flasks (75 cm 2 ) with 21 mL MSC medium, consisting of Dulbecco's modified Eagle's medium (DMEM) with 10% of fetal bovine serum (FBS), were seeded with 1 9 106 MSC/mL for primary culture.…”

Section: Sample Collection From Bone Marrow and Msc Culture And Expanmentioning

confidence: 99%

“…Results at 6 months were improved visual analogue score (VAS) on pain, walking distance, and joint space width on magnetic resonance imaging (MRI). 26,27 The second human experience was in our group of four patients; two men and two women 28 with moderate to severe OA of both knees. They received 8-9 million autologous MSC in their worse knee.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Mesenchymal stem cell therapy for knee osteoarthritis: 5 years follow‐up of three patients

et al. 2015

Self Cite

View full text Add to dashboard Cite

Aim: Osteoarthritis is a degenerative joint disease characterized by the destruction of joint cartilage. Mesenchymal stem cells (MSCs) are found in low numbers in normal cartilage, mainly in the superficial layer, acting as repairing agents. In OA, MSCs are seen in larger numbers, but act chaotic and are unable to repair the cartilage. The synovial membrane becomes inflamed and interacts with the cartilage. Transplanted MSC have the ability to normalize them, redirecting them to their normal function. In a preliminary study, we showed that MSC could improve knee OA in four patients at 6 months. This report shows their long-term follow-up at 5 years.Methods: One patient was lost to follow-up at 2 years and three were followed for 5 years. They were aged 55, 57, 65 and 54 years, and had moderate to severe knee osteoarthritis. The worse knee of each patient was injected with 8-9 9 10 6 MSC.Results: As previously reported, all parameters improved in transplant knees at 6 months (walking time, stair climbing, gelling pain, patella crepitus, flection contracture and the visual analogue score on pain). Then, they started gradually to deteriorate, but at 5 years they were still better than at baseline. PGA (Patient Global Assessment) improved from baseline to 5 years. The better knee at baseline (no MSC), continued its progression toward aggravation and at 5 years became the worse knee. Conclusion:Transplant knees were all in a rather advanced stage of OA. Earlier transplantation may give better results in long-term follow-up. This is what future studies have to demonstrate.

show abstract

Pulp and Dentin Regeneration

Nakashima

Huang

2013

Stem Cells in Craniofacial Development and Regeneration

View full text Add to dashboard Cite

Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients

Abstract: Results were encouraging, but not excellent. Improvement of the technique may improve the results.

Cited by 347 publications

References 15 publications

Rationale for Using Direct Bone Marrow Aspirate as a Proliferant for Regenerative Injection Therapy (Prolotherapy)

Rationale for Using Direct Bone Marrow Aspirate as a Proliferant for Regenerative Injection Therapy (Prolotherapy)

Mesenchymal stem cell therapy for knee osteoarthritis: 5 years follow‐up of three patients

Pulp and Dentin Regeneration

Contact Info

Product

Resources

About